Ghosh

UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor

Retrieved on: 
Monday, February 1, 2021

UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations

Key Points: 
  • UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz, Ph.D., as vice president of operations
    SOUTH SAN FRANCISCO, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Przemyslaw (Mike) Sapieha, Ph.D., as chief scientific advisor.
  • Mike is a long-term UNITY collaborator and an outstanding scientist whose work on the biological pathways impacting age-related eye diseases has been instrumental in the advancement of our Bcl-xL inhibitor, UBX1325, into the clinic, said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
  • I am looking forward to joining Anirvan and the UNITY team to contribute to the realization of that vision.
  • I am pleased to welcome Mike, Jason, and Nate to our leadership team as we drive UNITY forward.

UNITY Biotechnology Appoints Anirvan Ghosh, Ph.D. as Chief Executive Officer

Retrieved on: 
Monday, March 2, 2020

Dr. Ghosh joins UNITY from Biogen, where he served as Senior Vice President, Head of Research and Early Development.

Key Points: 
  • Dr. Ghosh joins UNITY from Biogen, where he served as Senior Vice President, Head of Research and Early Development.
  • Augmenting our already strong executive team with Anirvans insights and experience will ensure that UNITY has the opportunity to realize its full potential.
  • I look forward to continuing the journey and providing important continuity as I work with Anirvan in my capacity as Chairman.
  • UNITY President and co-founder, Nathaniel (Ned) E. David, Ph.D. added, I am really excited to work with Anirvan.